What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Breast cancer
Her main research concerns Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy.
Suzette Delaloge has included themes like Randomized controlled trial, Radiation therapy, Gynecology and Metastasis in her Breast cancer study.
Her work in Internal medicine covers topics such as Surgery which are related to areas like Clinical trial and Trastuzumab.
Her Oncology study combines topics in areas such as Neoadjuvant therapy, Circulating tumor cell, Docetaxel and Pathology.
Her Cancer study integrates concerns from other disciplines, such as Mutation, Germline, Clinical endpoint, Survival analysis and Family history.
Her studies examine the connections between Chemotherapy and genetics, as well as such issues in Anthracycline, with regards to Immunology, Immune system, Logistic regression, Nomogram and Stage.
Her most cited work include:
- Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. (2103 citations)
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation (1004 citations)
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer (772 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of investigation include Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy.
Suzette Delaloge studied Breast cancer and Surgery that intersect with Clinical trial.
The Oncology study combines topics in areas such as Randomized controlled trial, Neratinib, Capecitabine and Anthracycline.
Her Cancer study which covers Cancer research that intersects with Immune system.
Her Chemotherapy study frequently draws connections to other fields, such as Radiation therapy.
Her Metastatic breast cancer research incorporates themes from BRCA mutation and Progression-free survival.
She most often published in these fields:
- Internal medicine (60.37%)
- Breast cancer (57.52%)
- Oncology (52.85%)
What were the highlights of her more recent work (between 2018-2021)?
- Internal medicine (60.37%)
- Oncology (52.85%)
- Breast cancer (57.52%)
In recent papers she was focusing on the following fields of study:
Suzette Delaloge mainly focuses on Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer.
Her Oncology research focuses on Docetaxel and how it relates to Epirubicin.
Her work carried out in the field of Breast cancer brings together such families of science as Clinical endpoint, Quality of life, Prospective cohort study and Adjuvant therapy.
Intervention is closely connected to Psychological intervention in her research, which is encompassed under the umbrella topic of Cancer.
In her research, Lapatinib is intimately related to Capecitabine, which falls under the overarching field of Metastatic breast cancer.
Her work deals with themes such as Gene signature, Randomized controlled trial and Early breast cancer, which intersect with Chemotherapy.
Between 2018 and 2021, her most popular works were:
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (129 citations)
- Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. (56 citations)
- Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. (52 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
Internal medicine, Breast cancer, Oncology, Metastatic breast cancer and Cancer are her primary areas of study.
Her research integrates issues of Chemotherapy, Adjuvant therapy, Cohort, Adverse effect and Prospective cohort study in her study of Breast cancer.
Suzette Delaloge works mostly in the field of Chemotherapy, limiting it down to topics relating to Tamoxifen and, in certain cases, Randomization, Medical prescription and Therapeutic drug monitoring, as a part of the same area of interest.
Her study in Oncology is interdisciplinary in nature, drawing from both Transcriptome, Randomized controlled trial, Gene signature, Hazard ratio and Biomarker.
The study incorporates disciplines such as Taxane, Adjuvant and Anthracycline in addition to Randomized controlled trial.
Her studies deal with areas such as Genetic counseling, Susceptibility gene and Family history as well as Metastatic breast cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
